Status:
UNKNOWN
Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis
Lead Sponsor:
Universita di Verona
Conditions:
Chronic Plaque Psoriasis
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
It is a phase IV multicentric, placebo-controlled, clinical trial investigating the efficacy and safety of acitretin combined to efalizumab in the therapy of chronic plaque psoriasis. PASI 75 at week ...
Eligibility Criteria
Inclusion
- Men aged 18-70
- Women in postmenopausal
- Moderate to severe chronic plaque psoriasis in patients with contraindication, intolerance or non responsive to cyclosporine, methotrexate or PUVA
- PASI \> 10 e/o BSA (Body Surface Area) \> 10
Exclusion
- Drug induced psoriasis
- Pustular or erythrodermic psoriasis
- Fertile women
- Pregnancy or lactation
- cholesterol \> 230mg/dL e triglyceride \> 200 mg/dL
- Known intolerance to efalizumab and acitretin
- Serious infection at enrollement
- History of previous neoplasia
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2009
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00707070
Start Date
September 1 2008
End Date
October 1 2009
Last Update
June 30 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Univeristy Hospital
Verona, Italy, 37126